Close Menu

NEW YORK (GenomeWeb) – Startup Tymora Analytical Operations this month was awarded a Phase II SBIR grant from the National Institutes of Health to develop multiplexed and reverse-phase array versions of its pImago system for non-antibody-based detection of protein phosphorylation.

The two-year grant, which is worth $451,538 in its first year, will also be used to further develop the technology for high-throughput analysis of signaling pathways, with an eye toward applications in cancer drug development and treatment, according to Tymora President and CTO Anton Iliuk.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.